Office of Research
Innovation & Technology
The Office of Research Innovation & Technology Transfer (RITT) at Versiti Blood Research Institute protects technological advances and medical resources across Versiti, transforming them into discoveries that save and improve patient lives. We accomplish this research translation and product development efforts into new medical diagnostic tools for patients; new medical tools for physicians; new tools used for ongoing basic discovery efforts; and new and improved delivery of therapeutics and knowledge for physicians, scientists and people worldwide.
Tech transfer staff provide patent management, licensing and contract negotiation services to scientists and Versiti partners.
Versiti has a number of patented technologies currently available for licensing. We also have collections of antibodies, transgenic mice and other scientific materials available to the research community.
Versiti, in collaboration with regional tech transfer offices and other organizations in southeastern Wisconsin, has developed a series of web-based video learning modules designed to introduce researchers to the technology transfer process.
A safety improvement to existing Chimeric Antigen Receptor (CAR) therapy that controls cytokine release syndrome. Short peptides are cloned into existing CAR constructs.
Genetically engineered T cells from a patient's own tumor combined with chimeric antigen receptor and vaccine technology offers a lasting cure for solid tumors.
Improved DNA-based diagnostic assay to identify platelet-specific alloantigens involved in immune thrombocytopenias or platelet mismatch of mom and fetus during pregnancy.
Improved and simplified diagnostic assay for von Willebrand Disease (VWD) screening. No need for ristocetin, aggregometer, or platelet reagents, reducing assay costs and false positives, while improving reproducibility.
The novel link between the intracellular function of tissue-type plasminogen activator (tPA) and Apolipoprotein B (apoB) in hepatocytes shows great promise for developing a drug to lower all bad atherogenic lipoproteins by tPA fragments and reduce cardiovascular risk.
CRISPR customized platelets or cells with specific alloantigens for use in blood typing, diagnostics or platelet transfusions.
Versiti Blood Research Institute
8733 W. Watertown Plank Rd.
Milwaukee, WI 53226
Explore research at Versiti Blood Research Institute. Learn about our scientific programs, investigators, and shared resources that support discoveries in blood disorders, cancer, immune diseases, and transfusion medicine.